Stock 300942 SHENZHEN BIOEASY BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shenzhen Bioeasy Biotechnology Co., Ltd.

Equities

300942

CNE100004C78

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
7.59 CNY +0.40% Intraday chart for Shenzhen Bioeasy Biotechnology Co., Ltd. +8.74% -35.07%
25/04 Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
25/04 Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 11,569 6,871 4,686
Enterprise Value (EV) 1 10,928 6,561 4,450
P/E ratio 48.1 x 81.6 x -25.4 x
Yield 0.86% 0.12% -
Capitalization / Revenue 19.4 x 10 x 18.4 x
EV / Revenue 18.3 x 9.55 x 17.5 x
EV / EBITDA 42.5 x 74.9 x -87.3 x
EV / FCF 108 x -117 x -67.3 x
FCF Yield 0.93% -0.86% -1.49%
Price to Book 12.2 x 7.12 x 5.58 x
Nbr of stocks (in thousands) 4,00,860 4,00,860 4,00,860
Reference price 2 28.86 17.14 11.69
Announcement Date 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 204.9 239.2 258.5 597.5 686.9 254.1
EBITDA 1 73.13 82.73 71.9 257 87.58 -50.95
EBIT 1 68.65 77.99 66.47 248.1 76.28 -66.85
Operating Margin 33.5% 32.61% 25.72% 41.52% 11.1% -26.31%
Earnings before Tax (EBT) 1 84.68 106 73.94 268 94.89 -177.8
Net income 1 73.94 92.31 65.45 236.5 82.97 -184.9
Net margin 36.08% 38.59% 25.32% 39.58% 12.08% -72.77%
EPS 2 1.420 0.2600 0.1800 0.6000 0.2100 -0.4600
Free Cash Flow 1 24.97 8.168 -44.07 101.2 -56.19 -66.11
FCF margin 12.18% 3.42% -17.05% 16.93% -8.18% -26.02%
FCF Conversion (EBITDA) 34.14% 9.87% - 39.36% - -
FCF Conversion (Net income) 33.77% 8.85% - 42.77% - -
Dividend per Share - - 0.0450 0.2490 0.0212 -
Announcement Date 28/06/19 01/07/20 28/04/21 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 189 442 379 641 310 236
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 25 8.17 -44.1 101 -56.2 -66.1
ROE (net income / shareholders' equity) 43.8% 24.6% 12.2% 31.6% 8.65% -20.4%
ROA (Net income/ Total Assets) 18.2% 10.6% 6.53% 17.2% 3.92% -3.17%
Assets 1 405.5 867.8 1,002 1,377 2,119 5,839
Book Value Per Share 2 4.280 1.470 1.530 2.360 2.410 2.090
Cash Flow per Share 2 3.640 1.230 1.050 0.8500 0.6200 1.190
Capex 1 10.5 26.3 82.8 79.5 177 129
Capex / Sales 5.14% 10.99% 32.05% 13.31% 25.75% 50.63%
Announcement Date 28/06/19 01/07/20 28/04/21 26/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
SHENZHEN BIOEASY BIOTECHNOLOGY CO., LTD. Stock Shenzhen Bioeasy Biotechnology Co., Ltd.
-35.07% 420M
BIOMÉRIEUX Stock bioMérieux
-1.89% 12.5B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.67B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+21.82% 5.36B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.31% 5.26B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.89% 3.15B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.59B
VITROLIFE AB Stock Vitrolife AB
-10.02% 2.06B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 300942 Stock
  4. Financials Shenzhen Bioeasy Biotechnology Co., Ltd.